Arcadia Biosciences (NASDAQ:RKDA – Free Report) had its price target trimmed by HC Wainwright from $10.00 to $6.00 in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Arcadia Biosciences’ Q1 2025 earnings at ($0.58) EPS, Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($0.43) EPS.
A number of other research firms have also recently commented on RKDA. StockNews.com initiated coverage on shares of Arcadia Biosciences in a research report on Thursday. They issued a sell rating for the company. Lake Street Capital upgraded Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th.
Get Our Latest Stock Report on Arcadia Biosciences
Arcadia Biosciences Trading Up 3.0 %
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.74. The business had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.20 million. Arcadia Biosciences had a negative net margin of 129.74% and a negative return on equity of 84.27%. During the same period last year, the company posted ($3.83) EPS. As a group, sell-side analysts predict that Arcadia Biosciences will post -5.01 earnings per share for the current fiscal year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 5/20 – 5/24
- Financial Services Stocks Investing
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- What is a buyback in stocks? A comprehensive guide for investors
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.